MREO

MEREO BIOPHARMA GROUP PLC

MREO · CIK 1719714 · Annual (10-K) · Last 2 years

Financial Trends

Revenue$0M
20232024
Net Income−$43M
20232024
Operating CF−$33M
20232024
Free Cash Flow
20232024

Income Statement

MetricFY 2024FY 2023
Revenue$0.0B$0.0B
Cost of Revenue
Gross Profit
R&D Expense$0.0B$0.0B
SG&A Expense
Operating Income$-0.0B$-0.0B
Net Income$-0.0B$-0.0B
EPS (Basic)$-0.06$-0.04
EPS (Diluted)$-0.06$-0.04

Balance Sheet

MetricFY 2024FY 2023
Total Assets$0.1B$0.1B
Current Assets$0.1B$0.1B
Cash & Equivalents$0.1B$0.1B
Total Liabilities$0.0B$0.0B
Current Liabilities$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B

Cash Flow Statement

MetricFY 2024FY 2023
Operating Cash Flow$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B
Capital Expenditures$0.0B
Financing Cash Flow$0.0B$0.0B